Exact Sciences Corp
Exact Sciences Corp. develops and commercializes cancer screening and precision oncology tests used before, during, and after a cancer diagnosis. Its portfolio is anchored by Cologuard for colorectal cancer screening and Oncotype DX for treatment guidance, with newer products such as Cologuard Plus, Oncodetect, and Cancerguard expanding the pipeline.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNon-invasive cancer screening tests, primarily Cologuard and related screening offerings.
Tumor and therapy-selection tests, led by Oncotype DX and related oncology diagnostics.
Customers
Exact Sciences sells primarily to physicians, health systems, and other ordering providers that prescribe or manage cancer testing for patients. It also depends on payers and reimbursement programs because test adoption is tied to coverage, patient access, and collections. Internationally, it serves providers and patients through local ordering networks, with Germany and Japan highlighted as important growth markets for Oncotype DX.
They order Cologuard and related screening tests to expand colorectal cancer screening and close care gaps.
They order Oncotype DX and therapy-selection tests to guide treatment decisions after diagnosis.
They reimburse tests and strongly influence adoption through coverage, pricing, and payment timing.
They buy Oncotype DX and other tests in markets such as Germany and Japan where provider adoption is growing.
They are the end users of screening tests, especially where employer, provider, or care-gap outreach increases adherence.
Strategy
Exact Sciences is focused on expanding adoption of its current tests while launching new products that broaden its addressable market. Management is also investing in clinical trials, reimbursement, and partnerships to strengthen its screening and precision-oncology franchise and improve patient adherence.
Higher test volume improves revenue leverage and strengthens the installed provider base.
New products expand the company beyond its legacy screening franchise and diversify growth.
Coverage and clinical validation are essential for adoption in regulated diagnostics.
Screening volume depends on reaching more eligible patients and improving completion rates.
Geography
The company is heavily U.S.-centric: about 95% of employees are located in the United States, and most testing and commercial activity is centered there. It also has meaningful international exposure through Oncotype DX, including a German processing facility in Trier and growing ordering-provider activity outside the U.S., particularly in Japan. Geography matters because reimbursement, regulatory approval, and local lab processing all affect adoption and margins.
Risks
Exact Sciences faces reimbursement, regulatory, and execution risk because its products depend on payer coverage, clinical evidence, and successful commercialization. It also operates in a highly competitive diagnostics market where larger or better-funded rivals can pressure pricing, adoption, and innovation timelines. As a lab-based healthcare business, it is exposed to quality control, data security, and international expansion risks that can affect reputation and operating performance.
- Reimbursement uncertaintyImpact: HighLikelihood: Medium
Test demand and cash collection depend on payer coverage, pricing, and denials.
Exposure - Product development and regulatory executionImpact: HighLikelihood: Medium
New diagnostics require clinical validation, FDA pathways, and evidence generation before scaling.
Exposure - Cybersecurity and data privacyImpact: HighLikelihood: Medium
The company handles sensitive patient and payer data across internal systems and third parties.
Exposure - Competitive pressureImpact: MediumLikelihood: Medium
The market is rapidly evolving and competitors may launch alternative screening or oncology tests.
Exposure: Screening and precision oncology
- International operating riskImpact: MediumLikelihood: Medium
Foreign markets add regulatory, labor, operational, and collection complexity.
Exposure
Accounting
Judgemental itemsDiagnostic revenue depends on expected reimbursement, collections, and payer denials.
Impact: Can create prior-period adjustments and affect quarterly comparability.
Commercialized tests and licenses carry amortization that flows through cost of sales.
Impact: Affects gross margin and operating profit.
Pipeline development and trial programs are a material and judgmental expense area.
Impact: Can move operating expense trends and cash burn.
Acquisitions and product launches create assets that may be impaired if performance weakens.
Impact: Could cause non-cash charges and reduce equity.
Similar listed companies
Publicly listed companies with a comparable business focus.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Caris Life Sciences, Inc.
CAI · Services-Medical Laboratories
Caris Life Sciences is a Texas-based precision medicine company that uses molecular profiling, sequencing, and AI/ML analytics to help guide cancer diagnosis,…
Definitive Healthcare Corp.
DH · Services-Prepackaged Software
Guardant Health, Inc.
GH · Services-Medical Laboratories
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics.
Personalis, Inc.
PSNL · Services-Medical Laboratories
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Last updated: 24/09/2026